Danish drugmaker Novo Nordisk has approached the Delhi High Court seeking to restrain Sun Pharmaceutical Industries from manufacturing semaglutide, a GLP-1 drug used widely for type-2 diabetes management and long-term weight control.
According to ET Now, Novo Nordisk has filed a fresh plea asking the court to bar Sun Pharma from producing the molecule or any formulation derived from it. The matter is expected to be heard tomorrow.
Semaglutide, a blockbuster therapy globally, has been at the centre of multiple legal disputes in India. Earlier this week, the Delhi High Court refused to grant an interim injunction that Novo Nordisk had sought against Dr Reddy’s Laboratories (DRL). The court allowed DRL to continue manufacturing and exporting its semaglutide-based product while proceedings continue.
The latest petition expands the scope of the ongoing litigation to include Sun Pharma, one of India’s largest pharmaceutical manufacturers. The development comes amid rising global demand for GLP-1 therapies, with several Indian companies exploring opportunities to produce generic versions for international markets.
Novo Nordisk, meanwhile, is pushing for stronger protection of its intellectual property rights related to semaglutide in India, intensifying the legal battle ahead of the next hearing.
